AbCellera Biologics (ABCL) Operating Expenses (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Operating Expenses came in at $65.8 million in Q1 2026, down 1.59% YoY from $66.9 million in Q1 2025, and down 10.35% on a QoQ basis from $73.4 million in Q4 2025.
AbCellera Biologics (ABCL) Operating Expenses (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Operating Expenses data on file, last reported at $65.8 million in Q1 2026.
- Quarterly Operating Expenses fell 1.59% year-over-year to $65.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $291.2 million (down 15.76% YoY) and the FY2025 annual result came in at $292.2 million, down 14.95% from the prior year.
- Operating Expenses declined to $65.8 million in Q1 2026, from $73.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $100.8 million in Q2 2024 to a low of $54.3 million in Q2 2022.
- A 5-year average of $73.3 million and a median of $66.9 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 105.14% — and 2025, when it sank 33.85%.
- Tracing ABCL's Operating Expenses over 5 years: stood at $59.3 million in 2022, then climbed by 26.82% to $75.2 million in 2023, then increased by 3.42% to $77.8 million in 2024, then fell by 5.62% to $73.4 million in 2025, then slipped by 10.35% to $65.8 million in 2026.
- The last three Operating Expenses figures came in at $65.8 million (Q1 2026), $73.4 million (Q4 2025), and $85.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 66.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.83 Mn |
| Mar 31, 2026 | 65.83 Mn |
| Dec 31, 2025 | 73.44 Mn |
| Sep 30, 2025 | 85.23 Mn |
| Jun 30, 2025 | 66.67 Mn |
| Mar 31, 2025 | 66.90 Mn |
| Dec 31, 2024 | 77.81 Mn |
| Sep 30, 2024 | 100.17 Mn |
| Jun 30, 2024 | 100.78 Mn |
| Mar 31, 2024 | 64.85 Mn |
| Dec 31, 2023 | 75.23 Mn |
| Sep 30, 2023 | 61.49 Mn |
| Jun 30, 2023 | 61.45 Mn |
| Mar 31, 2023 | 77.07 Mn |
| Dec 31, 2022 | 59.32 Mn |
| Sep 30, 2022 | 63.65 Mn |
| Jun 30, 2022 | 54.31 Mn |
| Mar 31, 2022 | 91.63 Mn |
| Dec 31, 2021 | 57.78 Mn |
| Sep 30, 2021 | 33.60 Mn |